Gujarat Themis Biosyn QIP (28 Aug 2026)
Gujarat Themis Biosyn Limited closes QIP, approves 2,11,86,440 shares at ₹354 each
Gujarat Themis Biosyn · Pharmaceuticals & Biotechnology
Key highlights
- QIP issue period opened August 25, 2026; closure of the issue period approved August 28, 2026 after receipt of applications and escrow funds
- Issue price fixed at ₹354 per share (premium ₹353) for 2,11,86,440 equity shares, a discount of ₹18.57 (4.98%) on the ₹372.57 floor price
- Placement document dated August 28, 2026 adopted and posted on www.gtbl.in
Why it's rated notable: The filing confirms closure of the QIP and an issue price for 2,11,86,440 shares at Rs. 354 each but states no total amount, and at that price the issue is roughly ₹750 crore, which is at least medium under the ₹500 crore rule and below the 50% high bar against the ₹5,110 crore market value.
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Qualified Institutional Placement
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Gujarat Themis Biosyn
- Fundraise / allotmentNotableGujarat Themis Biosyn Limited announces dividend, fund raise, and AOA amendment
- Fundraise / allotmentNotableGujarat Themis Biosyn Ltd allots ₹585 crore NCDs via private placement on 16-09-2026
- Fundraise / allotmentNotableGujarat Themis Biosyn approves issuance of Non-Convertible Debentures up to ₹585 Cr
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentImagicaaworld EntertainmentImagicaaworld Entertainment reports Q2 & H1 FY27 financial results and strategic updates
- Fundraise / allotmentUnited Heat TransferUnited Heat Transfer Limited approves half-year financial results for Sept 2026
- Fundraise / allotmentJubilant PharmovaJubilant Pharmova reports Q2 and H1 FY27 financial results and operational updates
- Fundraise / allotmentNatural CapsulesNatural Capsules Limited approves Q2 2026 results and preferential allotment
- Fundraise / allotmentNatural CapsulesNatural Capsules Ltd announces Q2 FY27 results and approves preferential allotment
- Fundraise / allotmentDestiny Logistics & InfraDestiny Logistics & Infra Ltd announces key resignations, appointments, and warrant lapse
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.